Roman Butler Fullerton & Co’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $705K | Buy |
1,956
+27
| +1% | +$9.24K | 0.17% | 145 |
|
|
2026
Q1 | $675K | Buy |
1,929
+43
| +2% | +$15.3K | 0.19% | 133 |
|
|
2025
Q4 | $655K | Sell |
1,886
-41
| -2% | -$13K | 0.17% | 143 |
|
|
2025
Q3 | $562K | Sell |
1,927
-35
| -2% | -$10.2K | 0.15% | 145 |
|
|
2025
Q2 | $601K | Buy |
1,962
+31
| +2% | +$8.78K | 0.18% | 133 |
|
|
2025
Q1 | $570K | Buy |
1,931
+2
| +0.1% | +$591 | 0.22% | 113 |
|
|
2024
Q4 | $546K | Sell |
1,929
-182
| -9% | -$54K | 0.17% | 127 |
|
|
2024
Q3 | $686K | Sell |
2,111
-119
| -5% | -$38.9K | 0.21% | 112 |
|
|
2024
Q2 | $717K | Sell |
2,230
-516
| -19% | -$152K | 0.23% | 98 |
|
|
2024
Q1 | $747K | Buy |
2,746
+523
| +24% | +$153K | 0.28% | 88 |
|
|
2023
Q4 | $693K | Buy |
2,223
+18
| +0.8% | +$4.9K | 0.27% | 91 |
|
|
2023
Q3 | $627K | Buy |
2,205
+106
| +5% | +$26.5K | 0.3% | 89 |
|
|
2023
Q2 | $487K | Buy |
2,099
+16
| +0.8% | +$3.71K | 0.22% | 106 |
|
|
2023
Q1 | $510K | Buy |
2,083
+15
| +0.7% | +$3.68K | 0.25% | 106 |
|
|
2022
Q4 | $557K | Sell |
2,068
-7
| -0.3% | -$1.88K | 0.29% | 101 |
|
|
2022
Q3 | $509K | Buy |
2,075
+13
| +0.6% | +$3.15K | 0.32% | 94 |
|
|
2022
Q2 | $513K | Buy |
2,062
+13
| +0.6% | +$3.19K | 0.28% | 102 |
|
|
2022
Q1 | $496K | Buy |
2,049
+13
| +0.6% | +$2.99K | 0.23% | 114 |
|
|
2021
Q4 | $458K | Buy |
2,036
+14
| +0.7% | +$2.96K | 0.2% | 114 |
|
|
2021
Q3 | $411K | Buy |
2,022
+12
| +0.6% | +$2.76K | 0.19% | 124 |
|
|
2021
Q2 | $490K | Sell |
2,010
-20
| -1% | -$4.92K | 0.24% | 109 |
|
|
2021
Q1 | $510K | Hold |
2,030
| – | – | 0.26% | 110 |
|
|
2020
Q4 | $467K | Buy |
2,030
+55
| +3% | +$12.7K | 0.28% | 99 |
|
|
2020
Q3 | $502K | Buy |
1,975
+9
| +0.5% | +$2.23K | 0.33% | 92 |
|
|
2020
Q2 | $464K | Sell |
1,966
-2,379
| -55% | -$543K | 0.33% | 93 |
|
|
2020
Q1 | $881K | Sell |
4,345
-1,196
| -22% | -$261K | 0.78% | 44 |
|
|
2019
Q4 | $1.34M | Buy |
5,541
+14
| +0.3% | +$3.09K | 0.88% | 29 |
|
|
2019
Q3 | $1.07M | Sell |
5,527
-465
| -8% | -$89.3K | 0.74% | 41 |
|
|
2019
Q2 | $1.1M | Buy |
5,992
+1,550
| +35% | +$278K | 0.74% | 37 |
|
|
2019
Q1 | $844K | Buy |
4,442
+815
| +22% | +$156K | 0.59% | 54 |
|
|
2018
Q4 | $735K | Buy |
+3,627
| New | +$708K | 0.62% | 57 |
|
Other funds holding AMGN
Roman Butler Fullerton & Co's AMGN Position: Q2 2026 in Review
Roman Butler Fullerton & Co increased its Amgen (AMGN) stake by 1.4% in Q2 2026, buying an estimated $9.24K and bringing the position to 1,956 shares worth $705K. The position accounts for 0.17% of the portfolio, ranked #145.
Roman Butler Fullerton & Co first reported a position in AMGN in Q4 2018 and has held it in 31 quarters since. The position peaked at $1.34M in Q4 2019. 3,157 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.
- Roman Butler Fullerton & Co held 1,956 shares of Amgen worth $705K as of Q2 2026.
- Roman Butler Fullerton & Co bought 27 Amgen shares in Q2 2026, an estimated $9.24K.
- Amgen made up 0.17% of Roman Butler Fullerton & Co's portfolio in Q2 2026, its #145 holding.
- Roman Butler Fullerton & Co first reported a position in Amgen in Q4 2018 and has held it in 31 quarters since.
- Roman Butler Fullerton & Co's Amgen position peaked at $1.34M in Q4 2019.
- 3,157 funds tracked by Wall St. Rank held Amgen as of Q2 2026.
Based on Roman Butler Fullerton & Co's 13F filing for Q2 2026, filed 6 Aug 2026.